



PRESS RELEASE

ASN Contact: Christine Feheley
(202) 640-4638 | cfeheley@asn-online.org

**EMBARGOED FOR RELEASE UNTIL
NOVEMBER 3, 2022 AT 4:30 PM ET**

ANALYSIS LINKS IMPAIRED KIDNEY FUNCTION WITH COGNITIVE DISORDERS

Highlights

- In an analysis of data from the Framingham Heart Study, albuminuria (a marker of kidney disease) was associated with signs of silent stroke, and patients with albuminuria had a higher risk of developing mild cognitive impairment or dementia.
- Chronic kidney disease was not associated with markers of silent stroke but was associated with a higher risk of developing dementia.
- Results from the study will be presented at ASN Kidney Week 2022 November 3–November 6.

Orlando (November 3, 2022) — New research has demonstrated a link between kidney disease and the development of cognitive problems. The findings will be presented at ASN Kidney Week 2022 November 3–November 6.

The study relied on data from the population-based Framingham Heart Study. Among 2,738 participants without dementia, 187 (7%) had chronic kidney disease and 251 (9%) had albuminuria, a urinary marker of kidney disease. Albuminuria was associated with signs of silent stroke, and patients with albuminuria had a 65% higher risk of developing mild cognitive impairment or dementia. Chronic kidney disease was not associated with markers of silent cerebrovascular disease but was associated with a 51% higher risk of developing dementia.

“Our results highlight the importance of albuminuria as a cerebrovascular and cognitive risk factor and indicate that there may be additional shared disease mechanisms in the kidney and the brain beyond hypertension,” said corresponding author Dearbhla Kelly, MBBChBAO, MSc, DPhil, of St. James’s Hospital, Dublin, Ireland.

Study: “Associations of Impaired Kidney Function with Cerebral Small Vessel Disease and Cognitive Disorders: Findings from the Framingham Heart Study”

ASN Kidney Week 2022, the largest nephrology meeting of its kind, will provide a forum for nephrologists and other kidney health professionals to discuss the latest findings in research and engage in educational sessions related to advances in the care of patients with kidney diseases and related disorders.

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 132 countries. For more information, visit www.asn-online.org and follow us on [Facebook](#), [Twitter](#), [LinkedIn](#), and [Instagram](#).

###